Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor α

Cancer Research

Volumn 58, Issue 1, 1998, Pages 123-134

  Santoni Rugiu, Eric ^a   Jensen, Michael Rugaard ^a   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN D1; MESSENGER RNA; MYC PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; GENE DISRUPTION; GENE EXPRESSION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MITOSIS INDEX; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; CARRIER PROTEINS; CDC2 PROTEIN KINASE; CELL CYCLE PROTEINS; CELL DIVISION; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; E2F2 TRANSCRIPTION FACTOR; G1 PHASE; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MITOTIC INDEX; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; RETINOBLASTOMA PROTEIN; S PHASE; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR ALPHA; TRANSGENES;

EID: 0031963692     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Grisham, J. W. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis (Lond.), 18: 59-81, 1997.
2. Murakami, H., Sanderson, N., Nagy, P., Marino, P., Merlino, G. T., and Thorgeirsson, S. S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor α in hepatic oncogenesis. Cancer Res., 53: 1719-1723, 1993.
3. Santoni-Rugiu, E., Nagy, P., Jensen, M. R., Factor, V. M., and Thorgeirsson, S. S. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-α. Am. J. Pathol., 149: 407-428, 1996.
4. Lee, G-H., Merlino, G., and Fausto, N. Development of liver tumors in transforming growth factor α transgenic mice. Cancer Res., 52: 5162-5170, 1992.
5. Sandgren, E. P., Luetteke, N. C., Qiu, T. H., Palmiter, R. D., Brinster, R. L., and Lee, D. C. Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver. Mol. Cell. Biol., 13: 320-330, 1993.
6. Amundadottir, L. T., Johnson, M. D., Merlino, G., Smith, G. H., and Dickson, R. B. Synergistic interaction of transforming growth factor-α and c-myc in mouse mammary and salivary gland tumorigenesis. Cell Growth Differ. 6: 737-748, 1995.
7. Lee, L. W., Raymond, V. W., Tsao, M-S., Lee, D. C., Earp, H. S., and Grisham, J. W. Clonal segregation of tumorigenicity with over-expression of c-myc and transforming growth factor-α genes in chemically transformed rat liver epithelial cells. Cancer Res., 51: 5238-5244, 1991.
8. Collins Presnell, S., Thompson, M. T., and Strom, S. C. Investigation of the cooperative effects of transforming growth factor-α and c-myc overexpression in rat liver epithelial cells. Mol. Carcinog., 13: 233-244, 1995.
9. Schulte-Hermann, R., Grasl-Kraupp, B., and Bursch, W. Apoptosis and Hepatocarcinogenesis. In: R. L. Jirtle (ed.), Liver Regeneration and Carcinogenesis: Cellular and Molecular Mechanisms, pp. 141-178. New York: Academic Press, 1995.
10. Amati, B., and Land, H. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation, and death. Curr. Opin. Genet. Dev., 4: 102-108, 1994.
11. Packham, G., Porter, C. W., and Cleveland, J. L. c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene, 13: 461-469, 1996.
12. Askew, D. S., Ashmun, R. A., Simmons, B. C., and Cleveland, J. L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene, 6: 1915-1922, 1991.
13. Harrington, E. A., Bennet, M. R., Fanidi, A., and Evan, G. I. c-Myc induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J., 13: 3286-3295, 1994.
14. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
15. Bartek, J., Bartkova, J., and Lukas, J. The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol., 8: 805-814, 1996.
16. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 7: 812-821, 1995.
17. Nevins, J. R. A link between the Rb tumor suppressor protein and viral oncoproteins. Science (Washington DC), 258: 424-429, 1992.
18. Johnson, D. G., Ohtani, K., and Nevins, J. R. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev., 8: 1514-1525, 1994.
19. DeGregori, J., Leone, G., Ohtani, K., Miron, A., and Nevins, J. R. E2F1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev., 9: 2873-2887, 1995.
20. Johnson, D. G. Regulation of E2F1 expression by p130 (Rb2) and D-type cyclin kinase activity. Oncogene,11: 1685-1692, 1995.
21. La Thangue, N. B. DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem. Sci., 19: 108-114, 1994.
22. Bejiersbergen, R. L., and Bernards, R. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochem. Biophys. Acta, 1287: 103-120, 1996.
23. 1 state. Mol. Cell. Biol., 16: 6965-6976, 1996.
24. Dynlacht, B. D. Regulation of transcription by proteins that control the cell cycle. Nature (Lond.), 289: 149-152, 1997.
25. Oswald, F., Lovec, H., Moroy, T., and Lipp, M. E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Oncogene, 9: 2029-2036, 1994.
26. 1-S regulatory genes. Mol. Cell. Biol., 15: 4215-4224, 1995.
27. Botz, J., Zerfass-Thome, K., Spitkovsky, D., Delius, H., Vogt, B., Eilers, M., Hatzigeorgiou, A., and Jansen-Dürr, P. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol. Cell. Biol., 16: 3401-3409, 1996.
28. Krek, W., Ewen, M. E., Shirodkar, S., Arany, Z., Kaelin, W. G., and Livingston, D. M. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell, 78: 161-172, 1994.
29. Hateboer, G., Kerkhoven, R. M., Shvarts, A., Bernards, R., and Beijersbergen, R. L. Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev., 10: 2960-2970, 1996.
30. Hofmann, F., Martelli, F., Livingston, D. M., and Wang, Z. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev., 10: 2949-2959, 1996.
31. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
32. Nagy, P., Bisgaard, H. C., Santoni-Rugiu, E., and Thorgeirsson, S. S. In vivo infusion of growth factors enhances the mitogenic response of rat hepatic ductal (oval) cells after administration of 2-acetylaminofluorene. Hepatology. 23: 71-79, 1996.
33. Santoni-Rugiu, E., Preisegger, K. H., Kiss, A., Audolfsson, T., Shiota, G., Schmidt, E. V., and Thorgeirsson, S. S. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc. Natl. Acad. Sci. USA, 93: 9577-9582, 1996.
34. Li, Y., Slansky, J. E., Myers, D. J., Drinkwater, N. R., Kaelin, W. G., and Farnham, P. J. Cloning, chromosomal location, and characterization of mouse E2F1. Mol. Cell. Biol., 14: 1861-1869, 1994.
35. Spurr, N. K., Gough, A. C., and Lee, M. G. Cloning of the mouse homologue of the yeast cell cycle control gene cdc2. DNA Seq., 1: 49-54, 1990.
36. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
37. Quelle, D. E., Ashmun, R. A., Hannon, G. J., Rehberger, P. A., Trono, D., Richter, K. H., Walker, C., Beach, D., Sherr, C. J., and Serrano, M. Cloning and characterization of murine p16INK4a and p15IHK4b genes Oncogene, 11, 635-645, 1995.
38. 1 checkpoint. Mol. Cell. Biol., 16: 6917-6925, 1996.
39. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
40. Hsiao, K., McMahon, S. L., and Farnham, P. J. Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Mol. Cell. Biol., 8: 1526-1537, 1994.
41. Leone, G., DeGregori, J., Sears, R., Jakoi, L., and Nevins, J. R. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature (Lond.), 387: 422-426, 1997.
42. Sears, R., Ohtani, K., and Nevins, J. R. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol. Cell. Biol., 17: 5227-5235, 1997.
43. Zhang, X., Xu, H-J., Murakami, Y., Sachse, R., Yashima, K., Hirohashi, S., Hu, S-X., Benedict, W. F., and Sekiya, T. Deletions of chromosome 13q, mutations in retinoblastoama 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res., 54: 4177-4182, 1994.
44. Fujimoto, Y., Hampton, L. L., Wirth, P. J., Wang, N. J., Xie, J. P., and Thorgeirsson, S. S. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res., 54: 281-285, 1994.
45. Nishida, N., Fukuda, Y., Komeda, T., Kita, R., Sando, T., Furukawa, M., Amenomori, M., Shibagaki, I., Nakao, K., Ikenaga, M., and Ishizaki, K. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res., 54: 3107-3110, 1994.
46. INK4 in hepatocellular carcinoma. Hepatology, 24: 575-579, 1996.
47. 1. Mol. Cell. Biol., 16: 3698-3706, 1996.
48. Schwarz, J. K., Bassing, C. H., Kovesdi, I., Datto, M. B., Blazing, M., Gorge, S., Wang, X-F., and Nevins, J. R. Expression of the E2F1 transcription factor overcomes type β transforming growth factor-mediated growth suppression. Proc. Natl. Acad. Sci. USA. 92: 483-487, 1995.
49. Roussel, M. F., Davis, J. N., Cleveland, J. L., Ghysdael, J., and Hiebert, S. W. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. Oncogene, 9: 405-415, 1994.
50. Sargent, L. M., Sanderson, N. D., and Thorgeirsson, S. S. Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor a transgenes. Cancer Res., 56: 2137-2142, 1996.
51. Pasquinelli, C., Bhavani, K., and Chisari, F. V. Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice. Cancer Res., 52: 2823-2829, 1992.
52. Kita, R., Nishida, N., Fukuda, Y., Azechi, H., Matsuoka, Y., Komeda, T., Sando, T., Nakao, K., and Ishizaki, K. Infrequent alterations of the p16INK4A gene in liver cancer. Int. J. Cancer, 67: 176-180, 1996.
53. Loyer, P., Cariou, S., Glaise, D., Bilodeau, M., Baffet, G., and Guguen-Guillouzo, C. Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence for a mitogen restriction point in mid-late G1. J. Biol. Chem., 271: 11484-11492, 1996.
54. Gómez-Lechón, M. J., Guillén, I., Ponsoda, X., Fabra, R., Trullenque, R., Nakamura, T., and Castell, J. V. Cell cycle progression proteins (cyclins), oncogene expression, and signal transduction during the proliferative response of human hepatocytes to hepatocyte growth factor. Hepatology, 23: 1012-1019, 1996.
55. Fausto, N., and Webber, E. M. Liver regeneration. In: I. M. Arias, J. L. Boyer, N. Fausto, W. B. Jakoby, D. A. Schacter, and D. A. Shafritz (eds.), The Liver: Biology and Pathobiology, Ed. 3, pp. 1059-1084. New York: Raven Press, 1994.
56. Jansen-Dürr, P., Meichle, A., Steiner, P., Pagano, M., Finke, K., Botz, J., Wessbecher, J., Draetta, G., and Eilers, M. Differential modulation of cyclin gene expression by MYC. Proc. Natl. Acad. Sci. USA, 90: 3685-3689, 1993.
57. Daksis, J. I., Lu, R. Y., Facchini, L. M., Marhin, W. W., and Penn, L. J. Z. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene, 9: 3635-3645, 1994.
58. Philipp, A., Schneider, A., Väsrik, I., Finke, K., Xiong, Y., Beach, D., Alitalo, K., and Eilers, M. Repression of cyclin D1: a novel function of MYC. Mol. Cell. Biol., 14: 4032-4043, 1994.
59. Roussel, M. F., Theodoras, A. M., Pagano, M., and Sherr, C. J. Rescue of defective mitogenic signaling by D-type cyclins. Proc. Natl. Acad. Sci. USA, 92: 6837-6841, 1995.
60. Bodrug, S. E., Warner, B. J., Bath, M. L., Lindeman, G. J., Harris, A. W., and Adams, J. M. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J., 11: 2124-2130, 1994.
61. Lovec, H., Grzeschiczek, A., Kowalski, M. B., and Moroy, T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J., 13: 3487-3495, 1994.
62. Sandgren, E. P., Schroeder, J. A., Qui, T. H., Palmiter, R. D., Brinster, R. L., and Lee, D. C. Inhibition of mammary gland involution is associated with transforming growth factor α but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res., 55: 3915-3927, 1995.
63. Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., and Schmidt, E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (Lond.), 369: 669-671, 1994.
64. Robles, A. I., Larcher, F., Whalin, R. B., Murillas, R., Richie, E., Gimenez-Conti, I. B., Jorcano, J., and Conti, C. J. Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia. Proc. Natl. Acad. Sci. USA, 93: 7634-7638, 1996.
65. Ikeda, M-A., Jakoi, L., and Nevins, J. R. A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proc. Natl. Acad. Sci. USA, 93: 3215-3220, 1996.
66. Johnson, D. G., Schwarz, J. K., Cress, W. D., and Nevins, J. R. Expression of the transcription factor E2F1 induces quiescent cells to enter S phase. Nature (Lond.), 365: 349-352, 1993.
67. Qin, X-Q., Livingston, D. M., Kaelin, W. G., and Adams, P. D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad Sci. USA. 91: 10918-10922, 1994.
68. Shan, B., and Lee, W. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol., 14: 8166-8173, 1994.
69. Hiebert, S. W., Lipp, M., and Nevins, J. R. E1A-dependent transactivation of the human MYC promoter is mediated by the E2F factor. Proc. Natl. Acad. Sci. USA, 86: 3594-3598, 1989.
70. Brechot, C. Oncogenic activation of cyclin A. Curr. Opin. Genet. Dev., 3: 311-318, 1993.
71. Rudolph, B., Saffrich, R., Zwicker, J., Henglein, B., Müller, R., Ansorge, W., and Eilers, M. Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. EMBO J., 15: 3065-3076, 1996.
72. Singh, P., Wong, S. H., and Hong, W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J., 13: 3329-3338, 1994.
73. Xu, G., Livingston, D. M., and Krek, W. Multiple members of the E2F transcription factor family are the products of oncogenes. Proc. Natl. Acad. Sci. USA, 92: 1357-1361, 1994.
74. Johnson, D. G., Cress, W. D., Jakoi, L., and Nevins, J. R. Oncogenic capacity of the E2F1 gene. Proc. Natl. Acad. Sci. USA, 91: 12823-12827, 1994.
75. Joos, K., Lam, E. W., Bybee, A., Girling, R., Muller, R., and La Thangue, N. B. Proto-oncogenic properties of the DP family of proteins. Oncogene, 10: 1529-1536, 1995.
76. Lukas, J., Petersen, B. O., Holm, K., Bartek, J., and Helin, K. Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. Mol. Cell. Biol., 16: 1047-1057, 1996.
77. Field, S. J., Tsai, F-Y., Kuo, F., Zubiaga, A. M., Kaelin, W. G., Jr., Livingston, D. M., Orkin, S. H., and Greenberg, M. E. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell, 85: 549-561, 1996.
78. Yamasaki, L., Jacks, T., Bronson, R., Goillot, E., Harlow, E., and Dyson, N. J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell, 85: 537-548, 1996.
79. Saito, M., Helin, K., Valentine, M. B., Griffith, B. B., Willman, C. L., Harlow, E., and Look, T. Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics, 25: 130-138, 1995.
80. Guy, C. T., Zhou, W., Kaufman, S., and Robinson, M. O. E2F-1 blocks terminal differentiation and causes proliferation in transgenic megakaryocytes. Mol. Cell. Biol., 16: 685-693, 1996.
81. Coleman, A., Schneider-Broussard, R., Martinez, L., Conti, C., and Johnson, D. B. Overexpression of E2F-1 in epithelial tissues of transgenic mice. Proc. Am. Assoc. Cancer Res., 38: 439, 1997.
82. Wu, X., and Levine, A. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3602-3606, 1994.
83. Nip, J., Strom, D. K., Fee, B. E., Zambetti, G., Cleveland, J. L., and Hiebert, S. W. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol. Cell. Biol., 17: 1049-1056, 1997.
84. Hiebert, S. W., Packham, G., Strom, D. K., Haffner, R., Oren, M., Zambetti, G., and Cleveland, J. L. E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol. Celll Biol., 15: 6864-6874, 1995.